全文获取类型
收费全文 | 16504篇 |
免费 | 1339篇 |
国内免费 | 504篇 |
专业分类
耳鼻咽喉 | 174篇 |
儿科学 | 309篇 |
妇产科学 | 383篇 |
基础医学 | 2127篇 |
口腔科学 | 348篇 |
临床医学 | 1987篇 |
内科学 | 3019篇 |
皮肤病学 | 310篇 |
神经病学 | 1087篇 |
特种医学 | 798篇 |
外国民族医学 | 3篇 |
外科学 | 1964篇 |
综合类 | 1170篇 |
一般理论 | 2篇 |
预防医学 | 1053篇 |
眼科学 | 442篇 |
药学 | 1418篇 |
4篇 | |
中国医学 | 335篇 |
肿瘤学 | 1414篇 |
出版年
2024年 | 30篇 |
2023年 | 176篇 |
2022年 | 418篇 |
2021年 | 603篇 |
2020年 | 322篇 |
2019年 | 431篇 |
2018年 | 430篇 |
2017年 | 382篇 |
2016年 | 396篇 |
2015年 | 544篇 |
2014年 | 646篇 |
2013年 | 714篇 |
2012年 | 1139篇 |
2011年 | 1213篇 |
2010年 | 734篇 |
2009年 | 640篇 |
2008年 | 885篇 |
2007年 | 861篇 |
2006年 | 825篇 |
2005年 | 780篇 |
2004年 | 696篇 |
2003年 | 605篇 |
2002年 | 530篇 |
2001年 | 475篇 |
2000年 | 414篇 |
1999年 | 406篇 |
1998年 | 191篇 |
1997年 | 189篇 |
1996年 | 213篇 |
1995年 | 181篇 |
1994年 | 129篇 |
1993年 | 110篇 |
1992年 | 202篇 |
1991年 | 187篇 |
1990年 | 164篇 |
1989年 | 159篇 |
1988年 | 152篇 |
1987年 | 122篇 |
1986年 | 114篇 |
1985年 | 119篇 |
1984年 | 87篇 |
1983年 | 78篇 |
1982年 | 75篇 |
1981年 | 67篇 |
1980年 | 64篇 |
1979年 | 61篇 |
1978年 | 58篇 |
1977年 | 44篇 |
1975年 | 29篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized,placebo controlled trial 总被引:13,自引:0,他引:13
Cheah PY Liong ML Yuen KH Teh CL Khor T Yang JR Yap HW Krieger JN 《The Journal of urology》2003,169(2):592-596
PURPOSE: We evaluate terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome. MATERIALS AND METHODS: The study included 100, 20 to-50-year-old subjects who met the consensus criteria for chronic prostatitis/chronic pelvic pain syndrome and had not received previous alpha-blockers. Subjects were randomized to receive terazosin with dose escalation from 1 to 5 mg. daily or placebo for 14 weeks. The primary criterion for response was scoring 2 or less ("delighted-to-mostly satisfied") on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) quality of life item. The secondary criterion for response was greater than 50% reduction in NIH-CPSI pain score at 14 weeks. Other outcomes included total and NIH-CPSI domain scores, International Prostate Symptom Score, peak urinary flow rate, post-void residual urine and adverse effects. RESULTS: Using the primary criterion 24 of 43 evaluable subjects (56%) responded in the terazosin group compared to 14 of 43 (36%) in the placebo group (p = 0.03). Using the secondary criterion 26 of 43 subjects (60%) responded in the terazosin group compared to 16 of 43 (37%) in the placebo group (p = 0.03). The terazosin group had greater reductions (p <0.05) in NIH-CPSI total score, individual domain scores and International Prostate Symptom Score than the placebo group. There was no difference in peak urinary flow rate or post-void residual. In the terazosin group 18 patients (42%) had side effects compared to 9 (21%) in the placebo group (p = 0.04). CONCLUSIONS: Terazosin proved superior to placebo for patients with chronic prostatitis/chronic pelvic pain syndrome who had not received alpha-blockers previously. 相似文献
992.
Neurocutaneous melanomatosis with a rapidly deteriorating course 总被引:2,自引:0,他引:2
Chu WC Lee V Chan YL Shing MM Chik KW Li CK Ma KC 《AJNR. American journal of neuroradiology》2003,24(2):287-290
Neurocutaneous melanosis is a rare congenital syndrome characterized by large or multiple congenital melanocytic nevi and benign or malignant pigment cell tumors of the leptomeninges. The prognosis is extremely poor for symptomatic patients, even in the absence of malignant melanoma. We present serial MR imaging findings in the brain and spine of a child with congenital giant hairy nevi who developed progressive leptomeningeal melanomatosis and whose neurologic condition rapidly deteriorated. 相似文献
993.
994.
重组人白细胞介素-11预防化疗所致血小板减少的临床研究 总被引:17,自引:1,他引:16
目的 评价国产重组人白细胞介素 11(rhIL 11)预防肿瘤化疗患者血小板减少的疗效及不良反应。方法 采用随机双盲自身交叉对照研究方法 ,将试验药品和安慰剂分为A药和B药 ,入选患者随机分为AB组或BA组。在化疗结束后 2 4h开始用药 ,2 5 μg kg体重 ,皮下注射 ,每日 1次 ,连续用药 7~ 14d或至血小板计数≥ 30 0× 10 9 L。结果 有 118例可评价疗效。rhIL 11可显著升高化疗后血小板最低值和化疗第 2 1天血小板值 ,升高幅度分别达 6 0 .7%和 86 .1% (P <0 .0 0 1) ;治疗周期出现血小板减少 (<10 0× 10 9 L)的持续时间为 1.0± 2 .0d ,而对照周期为 6 .9± 5 .4d。主要不良反应为注射部位疼痛 (2 4 .6 % )、红肿 (16 .1% )、硬结 (11.9% )、结膜充血 (16 .1% )、水肿 (8.5 % )、心悸(6 .8% )、乏力 (5 .1% )等 ,大都程度较轻 ,无其他严重不良反应。结论 rhIL 11具有明显的促血小板生成作用 ,可显著减少肿瘤患者化疗后血小板减少的发生 ,缩短血小板减少的持续时间。不良反应较轻且较易处理。 相似文献
995.
Contributions of ATM mutations to familial breast and ovarian cancer 总被引:11,自引:0,他引:11
Thorstenson YR Roxas A Kroiss R Jenkins MA Yu KM Bachrich T Muhr D Wayne TL Chu G Davis RW Wagner TM Oefner PJ 《Cancer research》2003,63(12):3325-3333
This study addresses the prevalence of ATM mutations and the association with breast cancer in Austrian families selected for a history of breast or ovarian cancer or both [hereditary breast and ovarian cancer (HBOC)]. In 270 HBOC families previously screened for BRCA1 and BRCA2 mutations, 137 different sequence alterations of ATM were identified. Seven of these were mutations presumed to cause ataxia telangiectasia based on their effect on the ATM protein, including five that caused a protein truncation and two missense mutations in the catalytic kinase domain of the highly conserved COOH terminus of the protein. The seven mutations were found in 10 families (3.7%). In addition, one missense variant, L1420F, was observed in 13 HBOC families (4.8%) but was not observed in any of the 122 healthy volunteers with no history of breast cancer. In addition, the variant segregated with breast cancer in some of the families, suggesting that it may be pathogenic for breast cancer. Sixty-two additional variants of potential significance were observed in 65 HBOC families, but not in healthy controls. These variants included 24 sequence alterations with possible effects on splicing or protein-protein interactions. This study indicates that there is a significant prevalence of ATM mutations in breast and ovarian cancer families and adds to a growing body of evidence that ATM mutations confer increased susceptibility to breast cancer. 相似文献
996.
Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population 总被引:3,自引:0,他引:3
Wong WM Lam SK Cheung KL Tong TS Rozen P Young GP Chu KW Ho J Law WL Tung HM Choi HK Lee YM Lai KC Hu WH Chan CK Yuen MF Wong BC 《Cancer》2003,97(10):2420-2424
BACKGROUND: Most commercial fecal occult blood tests (FOBT) used for colorectal carcinoma screening of Western populations are guaiac-based, manually developed, subjective, and sensitive to dietary components. Preliminary studies demonstrated the unsuitability of these tests for screening a Chinese population. The goal of the current study was to evaluate the performance characteristics of a human hemoglobin-specific automated immunochemical FOBT, the Magstream 1000/Hem SP (Fujirebio, Inc., Tokyo, Japan), in a Chinese population referred for colonoscopy. METHODS: Two hundred fifty consecutive patients who were referred for colonoscopy and met the study inclusion criteria provided samples for the immunochemical FOBT (without dietary restrictions) from two successive stool specimens. Tests were developed with an automated instrument that had an adjustable sensitivity threshold. The sensitivity, specificity, and positive predictive value for detecting colorectal adenomas and carcinomas were calculated according to the manufacturer's instructions over a range of sensitivity levels. RESULTS: At the optimal threshold level, the sensitivity, specificity, and positive predictive value for detection of significant colorectal neoplasia (adenomas >or= 1.0 cm and carcinomas) were 62%, 93%, and 44%, respectively. The test was easy to use, and results did not depend on operator experience. CONCLUSIONS: The automated immunochemical FOBT used in the current study was a robust, convenient, and useful tool for colorectal carcinoma screening in the study population. 相似文献
997.
BACKGROUND: Costs associated with the provision of medical care continue to escalate. Therefore, providers must evaluate the cost-effectiveness and benefit to individual healthcare practices. The authors evaluated the immediate and short-term resource utilization needs of patients undergoing surgical intervention with curative or palliative intent. METHODS: Three hundred two patients undergoing surgery with therapeutic intent were observed from the time of admission for intervention until the time of death or until 6 months from the time of the surgical procedure. Surgeons preoperatively identified each case as either curative or palliative in intent. Demographic information, as well as the nature of all interactions with the cancer center, was recorded. RESULTS: Surgeons identified 58 (19%) procedures as palliative and 244 (81%) as curative in intent. Demographic characteristics between the two groups were similar, although recurrent or metastatic disease was more often present in palliative rather than curative patients (P = 0.0078) and palliative intent patients were more likely to have received previous therapy. During the 6-month period, 4690 encounters occurred with the cancer center. The mean number of encounters per patient in each group was similar, although curative intent patients were more likely to have visits with therapeutic intent including chemotherapy administration (P = 0.01), radiation (P = 0.003), or repeat surgical procedures (P = 0.006). In contrast, palliative patients were more likely to be admitted for management of symptoms (P = 0.0001) and had fewer hospital-free days than did curative patients (P = 0.0069). CONCLUSIONS: The average number of encounters for patients undergoing treatment of disease was not significantly different, suggesting that patients undergoing surgery with palliative intent do not require a greater amount of resources than curative intent patients. The nature of the interactions, however, was different, suggesting that resource needs are different and may need to be anticipated in the assessment of how better quality outcomes can be achieved in the palliative surgery setting. 相似文献
998.
Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer 总被引:1,自引:0,他引:1
Lamharzi N Johnson MM Goodman G Etzioni R Weiss NS Dightman DA Barnett M DiTommaso D Chen C 《International journal of cancer. Journal international du cancer》2003,105(4):480-483
In the prostate, the enzyme encoded by the SRD5A2 gene (5alpha-reductase) converts testosterone to dihydrotestosterone, a potent androgen that has been hypothesized to play a role in the genesis of prostate cancer. Several polymorphisms have been identified in the SRD5A2 gene, including a valine-to-leucine substitution (V89L) at codon 89, a variable number of TA dinucleotide repeats and a missense substitution at codon 49 resulting in an amino acid substitution of alanine with threonine (A49T). To investigate the influence of these polymorphisms on prostate cancer risk, we conducted a case-control study nested within the Beta-Carotene and Retinol Efficacy Trial. Genotypes were determined by PCR-based capillary electrophoresis using genomic DNA isolated from 300 cases and 300 controls matched on the basis of race, age at enrollment (within 5 years), enrollment study center and year of randomization. There was no association between V89L genotypes and prostate cancer risk. The age- and race-adjusted odds ratio (OR) associated with the VL and LL genotypes were 1.06 (95% confidence interval (CI) = 0.75-1.49) and 0.99 (95% CI = 0.57-1.73), respectively, as compared to the VV genotype. The age- and race-adjusted odds ratio for men having 1 TA(9) or TA(18) allele was 0.98 (95% CI = 0.64-1.48) when compared to men without TA repeats. The corresponding odds ratio for men without the TA(0) alleles was 0.68 (95% CI = 0.21-2.19). The age- and race-adjusted odds ratio associated with having at least 1 T allele at codon 49 was 1.11 (95% CI = 0.58-2.11), as compared to the AA genotype. Our results do not support the hypothesis that the V89L and A49T polymorphisms in the SRD5A2 gene are related to the risk of prostate cancer, but are compatible with the suggestion from earlier studies that men who are homozygous for the TA(9) or (18) alleles and men who have the TA(9)/TA(18) genotype are at a modestly reduced risk. 相似文献
999.
1000.
Feldman KA Stiles-Enos D Julian K Matyas BT Telford SR Chu MC Petersen LR Hayes EB 《Emerging infectious diseases》2003,9(3):350-354
We conducted a serosurvey of landscapers to determine if they were at increased risk for exposure to Francisella tularensis and to determine risk factors for infection. In Martha's Vineyard, Massachusetts, landscapers (n=132) were tested for anti-F. tularensis antibody and completed a questionnaire. For comparison, serum samples from three groups of nonlandscaper Martha's Vineyard residents (n=103, 99, and 108) were tested. Twelve landscapers (9.1%) were seropositive, compared with one person total from the comparison groups (prevalence ratio 9.0; 95% confidence interval 1.2 to 68.1; p=0.02). Of landscapers who used a power blower, 15% were seropositive, compared to 2% who did not use a power blower (prevalence ratio 9.2; 95% confidence interval 1.2 to 69.0; p=0.02). Seropositive landscapers worked more hours per week mowing and weed-whacking and mowed more lawns per week than their seronegative counterparts. Health-care workers in tularemia-endemic areas should consider tularemia as a diagnosis for landscapers with a febrile illness. 相似文献